PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32237115-7	2020	Coadministration of laquinimod with CYP3A inhibitors, ketoconazole, fluconazole, and cimetidine increased laquinimod area under the plasma concentration-time curve from time zero to infinity by approximately 3.1-, 2.5-, and 1.1-fold, respectively.	laquinimod	20-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-41	
21163185-5	2011	Laquinimod is metabolised primarily by the CYP3A4 enzyme in the liver.	laquinimod	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49	
15764719-0	2005	Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator.	laquinimod	74-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-19	
15764719-5	2005	Moreover, ketoconazole and troleandomycin, specific inhibitors of CYP3A4 metabolism, demonstrated a significant inhibition of laquinimod metabolism.	laquinimod	126-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72	
15764719-7	2005	In vitro interaction studies with CYP3A4 substrates and possible concomitant medication demonstrated that laquinimod inhibits the metabolism of ethinyl estradiol with an IC50 value of about 150 microM, which is high above the plasma level of laquinimod after clinically relevant doses.	laquinimod	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40	
15764719-9	2005	In conclusion, the present study demonstrates that laquinimod is a low affinity substrate for CYP3A4 in human liver microsomes.	laquinimod	51-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	94-100	
15764719-10	2005	The likelihood for in vivo effects of laquinimod on the metabolism of other CYP3A4 substrates is minor.	laquinimod	38-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82	
15764719-11	2005	However, inhibitory effects on the metabolism of laquinimod by potent and specific inhibitors of CYP3A4, such as ketoconazole, are anticipated and should be considered in the continued clinical program for laquinimod.	laquinimod	49-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103	
15764719-11	2005	However, inhibitory effects on the metabolism of laquinimod by potent and specific inhibitors of CYP3A4, such as ketoconazole, are anticipated and should be considered in the continued clinical program for laquinimod.	laquinimod	206-216	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103	
32237115-7	2020	Coadministration of laquinimod with CYP3A inhibitors, ketoconazole, fluconazole, and cimetidine increased laquinimod area under the plasma concentration-time curve from time zero to infinity by approximately 3.1-, 2.5-, and 1.1-fold, respectively.	laquinimod	106-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-41	
32237115-9	2020	These results indicate that coadministration of laquinimod with moderate to strong inhibitors of CYP3A or strong inducers of CYP3A may give rise to significant pharmacokinetic drug interactions.	laquinimod	48-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-102	
32237115-9	2020	These results indicate that coadministration of laquinimod with moderate to strong inhibitors of CYP3A or strong inducers of CYP3A may give rise to significant pharmacokinetic drug interactions.	laquinimod	48-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-130	
32237115-0	2020	The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.	laquinimod	72-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-19	
32237115-1	2020	Laquinimod, a neuroimmunomodulator, is extensively metabolized by cytochrome P450 (CYP) 3A4, and modulations of CYP3A4 activity may lead to alterations in the pharmacokinetics and/or clinical effects of laquinimod.	laquinimod	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-91	
32237115-1	2020	Laquinimod, a neuroimmunomodulator, is extensively metabolized by cytochrome P450 (CYP) 3A4, and modulations of CYP3A4 activity may lead to alterations in the pharmacokinetics and/or clinical effects of laquinimod.	laquinimod	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118	
32237115-1	2020	Laquinimod, a neuroimmunomodulator, is extensively metabolized by cytochrome P450 (CYP) 3A4, and modulations of CYP3A4 activity may lead to alterations in the pharmacokinetics and/or clinical effects of laquinimod.	laquinimod	203-213	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118	
32237115-2	2020	To determine the drug-drug interaction potential of laquinimod with CYP3A inhibitors and inducers, interaction assessments were conducted in healthy volunteers using single-dose administration of laquinimod before and after multiple dosing of CYP3A inhibitors (ketoconazole, fluconazole, and cimetidine) or a CYP3A4 inducer (rifampin).	laquinimod	52-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-73